Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Libramont-Chevigny – page 2

16 clinical trials in Libramont-Chevigny, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Libramont-Chevigny at a glance
16
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

16 trials in Libramont-Chevigny

Open in trial search

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Fallopian tube cancer+1

Not recruiting

Study on Treatment for Recurrent Platinum-Sensitive Ovarian, Peritoneal, or Fallopian Tube Cancer Using Carboplatin and Mirvetuximab Soravtansine in Eligible Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Ovarian cancer+1

Not recruiting

Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:MPS-102
  • Sponsor:Asso De Recherche Cancers Gynecologiques

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Libramont-Chevigny

What the registry says about research in the country

01 Oncology (Neoplasms)

Trials in Libramont‑Chevigny are evaluating new therapies for advanced platinum‑resistant epithelial ovarian cancer, high‑risk non‑muscle‑invasive bladder cancer, limited‑stage small cell lung cancer, as well as gastrointestinal and head‑and‑neck malignancies, with the aim of extending progression‑free and overall survival.

  • Novel immunotherapy combinations
  • Targeted agents based on tumor biomarkers
  • Comparative effectiveness of emerging drugs versus standard care
  • Strategies to prevent disease recurrence

These studies seek to bring innovative treatments to patients with aggressive cancers and to define next‑generation standards of care.

02 Cancer‑Associated Thrombosis (Hemic & Lymphatic)

A dedicated trial is assessing the ability of REGN7508 to prevent cancer‑associated thrombosis and reduce bleeding complications in individuals receiving cancer therapy, reflecting a focus on vascular safety alongside oncologic treatment.

  • Prevention of venous thromboembolism in solid tumour patients
  • Evaluation of bleeding risk management
  • Integration of antithrombotic therapy with chemotherapy
  • Impact on overall treatment outcomes

The project aims to improve supportive care by lowering clot‑related events that can interrupt cancer treatment.

03 Prostate Cancer (Male Urogenital)

Research tests the addition of sarup​arib (AZD5305) to radiation and androgen‑deprivation therapy for men with high‑risk or very high‑risk localized prostate cancer carrying a BRCA mutation, targeting metastasis‑free survival.

  • Combination of targeted PARP inhibition with standard radiotherapy
  • Assessment of metastasis‑free survival benefits
  • Genetic stratification of patients based on BRCA status
  • Evaluation of safety and tolerability in combination regimen

The goal is to personalize treatment for genetically defined high‑risk prostate cancer and reduce the chance of disease spread.

04 Symptom Management & Pathological Conditions

Some studies address broader pathological conditions, focusing on preventing myelosuppression with agents like trilaciclib during chemoradiation for limited‑stage small cell lung cancer, thereby protecting blood cell counts and improving quality of life.

  • Myelosuppression prevention during chemoradiotherapy
  • Maintenance of hematologic health during intensive treatment
  • Impact on patient‑reported outcomes
  • Potential to enable full treatment dosing

These investigations support better tolerability of aggressive cancer regimens, benefiting patients across multiple tumour types.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.